{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:35:25Z","timestamp":1792812925947,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,10,12]],"date-time":"2014-10-12T00:00:00Z","timestamp":1413072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s00415-014-7532-3","type":"journal-article","created":{"date-parts":[[2014,10,23]],"date-time":"2014-10-23T22:22:07Z","timestamp":1414102927000},"page":"1115-1119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":156,"title":["Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"262","author":[{"given":"Raffaele","family":"Iorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Damato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Emilio","family":"Alboini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Evoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,12]]},"reference":[{"key":"7532_CR1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/eci.12.34","volume":"8","author":"MN Meriggioli","year":"2012","unstructured":"Meriggioli MN, Sanders DB (2012) Muscle antibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol 8:427\u2013438","journal-title":"Expert Rev Clin Immunol"},{"key":"7532_CR2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","volume":"12","author":"JJ Verschuuren","year":"2013","unstructured":"Verschuuren JJ, Huijbers MG, Plomp JJ et al (2013) Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 12:918\u2013923","journal-title":"Autoimmun Rev"},{"key":"7532_CR3","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A et al (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893\u2013902","journal-title":"Eur J Neurol"},{"key":"7532_CR4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1196\/annals.1405.033","volume":"1132","author":"DB Drachman","year":"2008","unstructured":"Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA (2008) Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci 1132:305\u2013314","journal-title":"Ann N Y Acad Sci"},{"key":"7532_CR5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435\u2013445","journal-title":"Blood"},{"key":"7532_CR6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","volume":"9","author":"HM G\u00fcrcan","year":"2009","unstructured":"G\u00fcrcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR (2009) A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9:10\u201325","journal-title":"Int Immunopharmacol"},{"key":"7532_CR7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/cen3.12103","volume":"5","author":"R Iorio","year":"2014","unstructured":"Iorio R, Pittock SJ (2014) Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies. Clin Exp Neuroimmunol 5:175\u2013187","journal-title":"Clin Exp Neuroimmunol"},{"key":"7532_CR8","author":"R Iorio","year":"2014","unstructured":"Iorio R, Assenza G, Tombini M, Colicchio G, Della Marca G, Benvenga A, Damato V, Rossini PM, Vollono C, Plantone D, Marti A, Batocchi AP, Evoli A (2014) The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy. Eur J Neurol. doi: 10.1111\/ene.12529","journal-title":"Eur J Neurol"},{"key":"7532_CR9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","volume":"55","author":"F Zaja","year":"2000","unstructured":"Zaja F, Russo D, Fuga G, Perella G, Baccarani M (2000) Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55:1062\u20131063","journal-title":"Neurology"},{"key":"7532_CR10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","volume":"143","author":"M Wylam","year":"2003","unstructured":"Wylam M, Anderson P, Kuntz NL, Rodriguez V (2003) Successful treatment of refractory myasthenia gravis using Rituxomab: a pediatric case report. J Pediatr 143:674\u2013677","journal-title":"J Pediatr"},{"key":"7532_CR11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ajh.20169","volume":"77","author":"A Gajra","year":"2004","unstructured":"Gajra A, Vajpayee N, Grethlein SJ (2004) Response of myasthenia gravis to rituximab in a patient with non-hodgkin lymphoma. Am J Hematol 77:196\u2013197","journal-title":"Am J Hematol"},{"key":"7532_CR12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s00277-005-1050-4","volume":"84","author":"K Takagi","year":"2005","unstructured":"Takagi K, Yoshida A, Iwasaki H, Inoue H, Ueda A (2005) Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma. Ann Hematol 84:548\u2013550","journal-title":"Ann Hematol"},{"key":"7532_CR13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mus.20411","volume":"33","author":"PT Lin","year":"2006","unstructured":"Lin PT, Martin BA, Weinacker AB, So YT (2006) High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve 33:433\u2013435","journal-title":"Muscle Nerve"},{"key":"7532_CR14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","volume":"33","author":"B Hain","year":"2006","unstructured":"Hain B, Jordan K, Deschauer M, Zierz S (2006) Successful treatment of Musk-antibody positive myasthenia gravis with Rituximab. Muscle Nerve 33:575\u2013580","journal-title":"Muscle Nerve"},{"key":"7532_CR15","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-006-0442-2","volume":"254","author":"M Thakre","year":"2007","unstructured":"Thakre M, Inshasi J, Marashi M (2007) Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 254:968\u2013969","journal-title":"J Neurol"},{"issue":"11","key":"7532_CR16","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00415-007-0593-9","volume":"254","author":"A Chan","year":"2007","unstructured":"Chan A, Lee DH, Linker R, Mohr A, Toyka KV, Gold R (2007) Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol 254(11):1604\u20131606","journal-title":"J Neurol"},{"key":"7532_CR17","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jnnp.2006.093567","volume":"78","author":"WS Baek","year":"2007","unstructured":"Baek WS, Bashey A, Sheean GL (2007) Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J Neurol Neurosurg Psychiatry 78:771","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7532_CR18","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mus.21047","volume":"38","author":"S Kerkeni","year":"2008","unstructured":"Kerkeni S, Marotte H, Miossec P (2008) Improvement with Rituximab in a patient with both rheumatoid arthritis and myasthenia gravis. Muscle Nerve 38:1343\u20131345","journal-title":"Muscle Nerve"},{"key":"7532_CR19","first-page":"659","volume":"66","author":"MD StroberJ","year":"2009","unstructured":"StroberJ MD, Cowan MJ, Horn BN (2009) Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol 66:659\u2013661","journal-title":"Arch Neurol"},{"key":"7532_CR20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2009.02.357","volume":"280","author":"K Stieglbauer","year":"2009","unstructured":"Stieglbauer K, Topakian R, Sch\u00e4ffer V, Aichner FT (2009) Rituximab for myasthenia gravis. Three case reports and review of the literature. J Neurol Sci 280:120\u2013122","journal-title":"J Neurol Sci"},{"key":"7532_CR21","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.4076\/1757-1626-2-6609","volume":"2","author":"N Tzaribachev","year":"2009","unstructured":"Tzaribachev N, Schedel J, Koetter I, Kuemmerle-Deschner JB (2009) Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2:6609","journal-title":"Cases J"},{"key":"7532_CR22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12185-010-0503-2","volume":"91","author":"R Masroujeh","year":"2010","unstructured":"Masroujeh R, Otrock ZK, Yamout B, Jabbour MN, Bazarbachi A (2010) Myasthenia gravis developing in a patient with CNS lymphoma. Int J Hematol 91:522\u2013524","journal-title":"Int J Hematol"},{"key":"7532_CR23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/jnnp.2009.174888","volume":"82","author":"A Sadnicka","year":"2011","unstructured":"Sadnicka A, Reill MM, Mummery C, Brandner S, Hirsch N, Lunn MP (2011) Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis. J Neurol Neurosurg Psychiatry 82:230\u2013232","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7532_CR24","first-page":"77","volume":"17","author":"AYL Lau","year":"2011","unstructured":"Lau AYL, Chan AYY, Mok VCT (2011) Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody\u2013positive myasthenia gravis: response to cyclophosphamide and rituximab treatment. Hong Kong Med J 17:77\u201379","journal-title":"Hong Kong Med J"},{"key":"7532_CR25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1212\/WNL.0b013e31820d6290","volume":"76","author":"T Kuntzer","year":"2011","unstructured":"Kuntzer T, Carota A, Novy J, Cavassini M, Du Pasquier RA (2011) Rituximab is successful in an HIV-positive patient with Musk myasthenia gravis. Neurology 76:757\u2013758","journal-title":"Neurology"},{"key":"7532_CR26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pediatrneurol.2012.05.017","volume":"47","author":"R Koul","year":"2012","unstructured":"Koul R, Al Futaisi A, Abdwani R (2012) Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature. Pediatr Neurol 47:209\u2013212","journal-title":"Pediatr Neurol"},{"key":"7532_CR27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/mus.23657","volume":"47","author":"M Jakubikova","year":"2013","unstructured":"Jakubikova M, Pitha J, Latta J, Ehler E, Schutzner J (2013) Myasthenia gravis, Castleman disease, pemphigus and anti-phospholipid syndrome. Muscle Nerve 47:447\u2013451","journal-title":"Muscle Nerve"},{"key":"7532_CR28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.nmd.2013.03.014","volume":"23","author":"D Renard","year":"2013","unstructured":"Renard D, Cornillet L, Castelnovo G (2013) Myocardial infarction after rituximab infusion. Neuromuscul Disord 23:599\u2013601","journal-title":"Neuromuscul Disord"},{"key":"7532_CR29","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/mus.24063","volume":"48","author":"JS Yi","year":"2013","unstructured":"Yi JS, Decroos EC, Sanders DB, Weinhold KJ, Guptill JT (2013) Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. Muscle Nerve 48:992\u2013993","journal-title":"Muscle Nerve"},{"key":"7532_CR30","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.23951","volume":"49","author":"F Sun","year":"2014","unstructured":"Sun F, Ladha SS, Yang L, Liu Q, Shi SX, Su N, Bomprezzi R, Shi FD (2014) Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis. Muscle Nerve 49:487\u2013494","journal-title":"Muscle Nerve"},{"key":"7532_CR31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RB, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Neurology 55:16\u201323","journal-title":"Neurology"},{"key":"7532_CR32","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","volume":"112","author":"R Stasi","year":"2008","unstructured":"Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, Amadori S (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112:1147\u20131150","journal-title":"Blood"},{"key":"7532_CR33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.berh.2011.10.005","volume":"25","author":"MJ Leandro","year":"2011","unstructured":"Leandro MJ, Becerra-Fernandez E (2011) B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 25:535\u2013548","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"7532_CR34","doi-asserted-by":"crossref","unstructured":"Cobo-Ib\u00e1\u00f1ez T, Loza-Santamar\u00eda E, Pego-Reigosa JM, Marqu\u00e9s AO, R\u00faa-Figueroa I, Fern\u00e1ndez-Nebro A, C\u00e1liz RC, L\u00f3pez Longo FJ, Mu\u00f1oz-Fern\u00e1ndez S (2014) Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum (Epub ahead of print)","DOI":"10.1016\/j.semarthrit.2014.04.002"},{"issue":"2","key":"7532_CR35","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54(2):613\u2013620","journal-title":"Arthritis Rheum"},{"key":"7532_CR36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2006.12.006","volume":"123","author":"PP Sfikakis","year":"2007","unstructured":"Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN (2007) Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 123:66\u201373","journal-title":"Clin Immunol"},{"key":"7532_CR37","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00415-013-6987-y","volume":"260","author":"V Catzola","year":"2013","unstructured":"Catzola V, Battaglia A, Buzzonetti A, Fossati M, Scuderi F, Fattorossi A, Evoli A (2013) Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. J Neurol 260:2163\u20132165","journal-title":"J Neurol"},{"key":"7532_CR38","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.autrev.2010.07.006","volume":"9","author":"M Benucci","year":"2010","unstructured":"Benucci M, Manfredi M, Puttini PS, Atzeni F (2010) Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today? Autoimmun Rev 9:801\u2013803","journal-title":"Autoimmun Rev"},{"key":"7532_CR39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/cyto.990140212","volume":"14","author":"LE Hultin","year":"1993","unstructured":"Hultin LE, Hausner MA, Hultin PM, Giorgi JV (1993) CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 14:196\u2013204","journal-title":"Cytometry"},{"key":"7532_CR40","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1073\/pnas.1001074107","volume":"107","author":"H Huang","year":"2010","unstructured":"Huang H, Benoist C, Mathis D (2010) Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci USA 107:4658\u20134663","journal-title":"Proc Natl Acad Sci USA"},{"key":"7532_CR41","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.4049\/jimmunol.1202317","volume":"189","author":"O Winter","year":"2012","unstructured":"Winter O, Dame C, Jundt F, Hiepe F (2012) Pathogenic long-lived plasma cells their survival niches in autoimmunity, malignancy, and allergy. J Immunol 189:5105\u20135111","journal-title":"J Immunol"},{"key":"7532_CR42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","volume":"78","author":"J D\u00edaz-Manera","year":"2012","unstructured":"D\u00edaz-Manera J, Mart\u00ednez-Hern\u00e1ndez E, Querol L, Klooster R, Rojas-Garc\u00eda R, Su\u00e1rez-Calvet X, Mu\u00f1oz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E, Ju\u00e1rez C, Verschuuren JJ, Illa I (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78:189\u2013193","journal-title":"Neurology"},{"issue":"7","key":"7532_CR43","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"HERMES Trial Group, Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676\u2013688","journal-title":"N Engl J Med"},{"key":"7532_CR44","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fimmu.2013.00494","volume":"4","author":"M Mah\u00e9vas","year":"2013","unstructured":"Mah\u00e9vas M, Michel M, Weill JC, Reynaud CA (2013) Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy. Front Immunol 4:494","journal-title":"Front Immunol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-014-7532-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-014-7532-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-014-7532-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T23:19:31Z","timestamp":1598397571000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-014-7532-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,12]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["7532"],"URL":"https:\/\/doi.org\/10.1007\/s00415-014-7532-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.721807471.793527302","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,12]]}}}